# Research and development investments for biologics independently developed by US biotechnology startups, 2017–2023

## TL;DR

This paper estimates the median investment of $304.1 million needed for US biotech startups to independently develop FDA-approved biologics, highlighting the financial scale of such innovation.

## Contribution

The paper provides the first empirical estimate of R&D investment required for independent biologic drug development by US biotech startups.

## Key findings

- The median investment per FDA-approved biologic was $304.1 million, including costs of failures.
- Nine biotech startups developed 13 drugs independently without acquisition or licensing.
- Priority review by the FDA was used as an indicator of innovation in the analysis.

## Abstract

Despite policy interest in pharmaceutical innovation, little is known about the investment needed for venture capital–backed startups to develop innovative biologics, a growing segment of the pharmaceutical marketplace.

In a cross-sectional analysis of Food and Drug Administration (FDA) drug approval data, investment deal records, and clinical trials data, we estimated the investment needed for a biotechnology startup company to independently develop a biologic approved by the US FDA with priority review, an indicator of innovation. To isolate a homogenous set of cases, the sample focused on independent drug development of 13 drugs by 9 biotechnology startup companies that retained ownership of the drug from the start of development to FDA approval without being acquired or licensing the product.

We found that the median investment per FDA-approved biologic was $304.1 million (IQR: $289.9–$790.3 million) in uncapitalized costs, accounting for the cost of failures.

This estimate represents the direct drug R&D investment needed for independent development of innovative biologic products by biotechnology startup companies.